Previous 10 | Next 10 |
Phase 2 Trials in Relapsed/Refractory and Frontline Settings Planned, APVO436 to be administered in Combination with Emerging Standard of Care New Data Adds to Growing Body of Clinical Evidence in Support of APVO436 Clinical Potential SEATTLE, WA / ACCESSWIRE / July 18, 2023 / Aptevo Th...
2023-05-11 09:24:36 ET Aptevo Therapeutics press release ( NASDAQ: APVO ): Q1 GAAP EPS of $0.26 beats by $1.45 . Aptevo had cash and cash equivalents as of March 31, 2023 totaling $25.3 million. For further details see: Aptevo Therapeutics GAAP EPS of $0.26 b...
Company Achieves Multiple Clinical and Preclinical Milestones and Raises $9.7 Million in Non-Dilutive Funding, Eliminates Balance Sheet Debt Introduces Novel Compound APVO711, Dual Mechanism of Action Includes Both Checkpoint Inhibitor and T Cell Stimulator SEATTLE, WA / ACCESSWIRE / May...
2023-03-30 09:10:45 ET Aptevo Therapeutics press release ( NASDAQ: APVO ): FY GAAP EPS of $1.57 beats by $0.64 . Revenue of $3.11M (-74.7% Y/Y) in-line. Aptevo had cash and cash equivalents as of December 31, 2022 totaling $22.6 million. For further details s...
2023-03-30 07:47:01 ET Aptevo Therapeutics ( NASDAQ: APVO ) has raised $9.6M in non-dilutive funding, extending its cash runway beyond 12 months with an additional $50K possible based on IXINITY sales in 1Q 23. The company raised this funding by closing a transaction ...
Company Achieves Multiple Clinical and Scientific Milestones in 2022, Poised for APVO436 Phase 2 in AML 2H23, ALG.APV-527 dosing initiated 1Q23 for Solid Tumors SEATTLE, WA / ACCESSWIRE / March 30, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused ...
Completes Sale of IXINITY Deferred Payments and Portion of Milestones from Medexus to XOMA Corporation SEATTLE, WA / ACCESSWIRE / March 30, 2023 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-onc...
Trial to Evaluate Safety, Tolerability and Clinical Activity in Solid Tumors Expressing 5T4 LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / February 13, 2023 / Alligator Bioscience AB ("Alligator") (Nasdaq Stockholm: ATORX) and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced the d...
New PD-L1 x CD40 Candidate Built on Proprietary ADAPTIR™ Platform, Enters Pre-Clinical Pipeline SEATTLE, WA / ACCESSWIRE / January 9, 2023 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-...
This week will be one of the most volatile weeks of the year. It won’t matter if you’re trading penny stocks or not, the final round of major economic data and central bank meetings from the FOMC are front and center. We’ve also got another rate hike decision coming and more ...
News, Short Squeeze, Breakout and More Instantly...
Aptevo Therapeutics Inc. Company Name:
APVO Stock Symbol:
NASDAQ Market:
Aptevo Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 113.3% to $0.3178 on volume of 162,323,665 shares NVIDIA Corporation (NVDA) rose 0.8% to $118.92 on volume of 44,858,282 shares Maxeon Solar Technologies Ltd. (MAXN) rose 8.5% to $0.2648 on volume of 43,008,...
2024-07-18 06:16:00 ET 3 Tips for Using RSI When Investing in Penny Stocks Relative Strength Index (RSI) is a powerful tool for evaluating the momentum of stocks, and it can be particularly effective when investing in penny stocks . Penny stocks offer unique opportunities due to the...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...